SCHEMBL22266240

SCHEMBL22266240

NC(=O)CCCOCCCO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.48
TSHR P16473 3/20 0.37
MAPK1 P28482 1/20 0.36
CAMK2A Q9UQM7 1/20 0.36
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
KMT2A Q03164 5/20 0.35
MEN1 O00255 3/20 0.35
GPR84 Q9NQS5 1/20 0.33
FFAR1 O14842 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
THRB P10828 1/20 0.33
HTT P42858 1/20 0.33
MAPT P10636 1/20 0.33
TARDBP Q13148 1/20 0.31
FAAH O00519 1/20 0.30
TP53 P04637 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22266261 0.93 GAA (0.57) GAATSHRMAPK1CAMK2ACYP4F2
SCHEMBL22266255 0.93 GAA (0.57) GAATSHRMAPK1CAMK2ACYP4F2
SCHEMBL22266233 0.93 GAA (0.47) GAATSHRMAPK1CAMK2ACYP4F2
SCHEMBL11143011 0.91 GAA (0.46) GAATSHRMAPK1CAMK2ACYP4F2
SCHEMBL10706576 0.91 GAA (0.60) GAATSHRMAPK1CAMK2ACYP4F2
SCHEMBL22266248 0.91 GAA (0.60) GAATSHRMAPK1CAMK2ACYP4F2
SCHEMBL8883206 0.90 TSHR (0.50) GAATSHRMAPK1CAMK2ACYP4F2
SCHEMBL27819968 0.89 GAA (0.40) GAATSHRMAPK1KMT2AMEN1
SCHEMBL22266242 0.88 TSHR (0.48) GAATSHRMAPK1CYP4F2CYP4A11
SCHEMBL28674740 0.88 MEN1 (0.52) GAATSHRMAPK1CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2020-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL GAA 1531/4885TSHR 2304/4885MAPK1 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.